Merck and Inctye jointly carry out clinical trials of the drug combo treatment with favorable outcomes
Category: #health  By Dhananjay Punekar  Date: 2017-09-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck and Inctye jointly carry out clinical trials of the drug combo treatment with favorable outcomes

Merck & Company, a major pharma giant and Incyte Corporation, reputed to be one of the key players in North America pharmaceutical industry, have achieved positive outcomes from their clinical experiments performed on the patients suffering from advanced stages of skin cancer. In these tests, both the firms combined their drugs, Keytruda and epacadostat, for treating the cancer patients. As per the data obtained from the trials, patients treated with the drug combination exhibited a response rate of nearly 56% and progression-free survival (PFS) of about 12.4 months. The PFS at the half-yearly stage was at 65%, 52% at 12 months, and 49% at 18 months.

As per the results derived from the clinical trials, thirty-five from among sixty-three skin cancer patients, who were treated with the medicine combination, had experienced the benefit of the combo treatment. The cancerous tumors from nine of these thirty-five patients were eliminated altogether after the combined drug treatment, while a partial response was witnessed in the rest of the patients.

The results derived from the recently conducted ECHO-202 trials has thus supported the earlier findings and implied that the new drug therapy used for treating patients suffering from advanced melanoma has bright future prospects. Statistics have displayed that the new combination biological therapy has indeed achieved high response rates and has depicted a substantial rise in the progression-free survival, which keytruda or epacasostat may not have been able to achieve successfully, if applied all by themselves.

For the record, Incyte Corporation’s Epacadostat has achieved a wide acclaim across the pharmaceutical sector, as a drug with high cancer treating potential. Its early trials on the cancer patients produced favorable outcomes that had a direct impact on the firm’s share prices. On the other hand, Merck’s keytruda has also brought about a substantial share price upswing, with its utilization in the treatment of advanced melanoma, bladder cancer, non-small cell lung cancer, kidney cancer, and head & neck cancer. Research is being carried on the drug to discover its ability of treating various other cancer types and measure the effects of the drug treatment after combining keytruda with its other counterparts.

This move will enable more pharma and biotechnology firms to follow suit. These breakthroughs will provide impetus to cancer research activities and help in bringing about a medical revolution, say experts. The paradigm shift is likely to help in the complete elimination of cancer in the decades to come.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...